Rigotti NA, Benowitz NL, Prochaska JJ, et al. Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial. JAMA Intern Med. Published online April 21, 2025. doi:10.1001/jamainternmed.2025.0628

https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2832701

“In a replication randomized clinical trial of 792 adults who smoked 10 or more cigarettes daily and received behavioral support, both 6- and 12-week cytisinicline regimens were more effective than placebo, producing significantly higher continuous smoking abstinence rates than placebo at the end of drug treatment and through 24 weeks.”

“These results demonstrate the high smoking cessation efficacy and excellent tolerability of cytisinicline, confirm its ability to reduce nicotine craving, and support adoption of cytisinicline as a smoking cessation medication.”

TRC Research Commentary

E-cigarettes: US Supreme Court upholds ban on flavoured liquids
BMJ 2025; 389 doi: https://doi.org/10.1136/bmj.r679 (Published 04 April 2025)
Cite this as: BMJ 2025;389:r679

https://www.politico.com/news/2025/04/02/fda-vapes-supreme-court-ruling-00006170

The Supreme Court upheld a past FDA decision banning flavored vapes. It ruled unanimously Wednesday that the FDA properly refused to approve two e-cigarette companies’ flavored vape products because regulators determined they were too great a risk to public health.

Comment: Restrictions on flavored E-cigarette products are becoming more common worldwide since these products are known to appeal to children. Stephen Hamann